Cellular pharmacology of lipophilic anthracyclines in human tumor cells in culture selected for resistance to doxorubicin

Anti-Cancer Drugs

Volumn 8, Issue 6, 1997, Pages 610-617

  Bennis, Sanae ^a,b   Faure, Pascale ^a   Chapey, Christiane ^a   Hu, Yan Ping ^a   Fourche, Jeanne ^a   El Yamani, Jamel ^b   Robert, Jacques ^a  

^a INSTITUT BERGONIÉ   (France)

^b Fac des Sci et Techniques Saiss ^*  (Morocco)

Author keywords

Anthracyclines; In vitro cytotoxicity; Multidrug resistance

Indexed keywords

2,4 BIS(ALLYLAMINO) 6 [4 [[2,2 BIS(4 FLUOROPHENYL)ETHYL]AMINO]PIPERIDINO] 1,3,5 TRIAZINE; ANTHRACYCLINE DERIVATIVE; DOXORUBICIN; IDARUBICIN; PIRARUBICIN; QUININE; VERAPAMIL;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACCUMULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; TUMOR CELL LINE;

ANTHRACYCLINES; ANTIBIOTICS, ANTINEOPLASTIC; CELL DIVISION; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; IDARUBICIN; P-GLYCOPROTEIN; TUMOR CELLS, CULTURED; VERAPAMIL;

EID: 0030867812     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199707000-00009     Document Type: Article

References (25)

1. Pastan I, Gottesman MM. Multidrug resistance. Annu Rev Med 1991: 42: 277-86.
2. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993; 62: 385-427.
3. Georges E, Sharon FJ, Ling V. Multidrug resistance and chemosensitization. Therapeutic implications for cancer chemotherapy. Adv Pharmacol 1990; 21: 185-220.
4. Berman E, Heller G, Santors JA, et al. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed myelogenous leukaemia. Blood 1991; 77: 1666-74.
5. Hérait P, Poutignat N, Marty M, Bugat R. Early assessment of a new anticancer drug analogue. The french experience with pirarubicin. Eur J Cancer 1992; 28A: 1670-76.
6. Casazza AM. Preclinical selection of new anthracyclines. Cancer Treat Rep 1986; 70: 43-9.
7. Priebe W, Perez-Soler R. Design and tumor targeting of anthracyclines able to overcome multidrug resistance: a double advantage approach. Pharmacol Ther 1993; 60: 215-34.
8. Facchetti I, Grandi M, Cucchi P, Geroni C, Penco S, Vigevani A. Influence of lipophilicity on cytotoxicity of anthracyclines in LoVo and LoVo/Dx human cell lines. Anticancer Drug Des 1991; 6: 385-97.
9. Skovsgaard T, Nissen NI. Membrane transport of anthracyclines. Pharmacol Ther 1982; 18: 293-311.
10. Mankhetkorn S, Dubru F, Hesschenbrouck J, Fiallo M, Garnier-Suillerot A. Relation among the resistance factor, kinetics of uptake, and kinetics of the P-glycoprotein-mediated efflux of doxorubicin in multidrug-resistant K562 cells. Mol Pharmacol 1996; 49: 532-9.
11. Soule HD, Vazquez J, Long A, Albert S, Brennan M. A human cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst 1973; 51: 1409-16.
12. Batist G, Tulpule A, Sinha BK, Katki AG, Myers CE, Cowan KH. Overexpresion of a novel anionic gluthatione transferase in multidrug-resistant human breast cancer cells. J Biol Chem 1986; 261: 15544-9.
13. Lozzio CB, Lozzio BB. Chronic myelogenous leukemia cell line with positive Philadelphia chromosome. Blood 1975; 45: 321-4.
14. Tsuruo T, lida-Saito H, Kawabata H, Oh-Hara T, Hamada H, Tsuruo T. Characteristics of resistance to adriamycin in human myelogenous leukemia K562 resistant to adriamycin and isolated clones. Jpn J Cancer Res 1986; 77: 682-92.
15. Schott B, Robert J. Comparative cytotoxicity, DNA synthesis inhibition, and drug incorporation of eight anthracyclines in a model of doxorubicin-sensitive and resistant rat glioblastoma cells. Biochem Pharmacol 1989; 38: 167-72.
16. Friche E, Jensen PB, Roed H, Skoosgaard T, Nossen NI. In vitro circumvention of anthracycline resistance in Ehrlich ascites tumor by anthracycline analogues. Biochem Pharmacol 1990; 39: 1721-8.
17. Zijlstra JG, Meijer C, Timmer-Bosscha H, Le TKP, de Vries EGE, Mulder NH. Activity of 7 anthracycline-related compounds in a doxorubicin-sensitive human small cell lung cancer line and its doxorubicin-resistant descendant. EurJ Resp Dis 1987; 70: 53-5.
18. Frézard F, Garnier-Suillerot A. Comparison of the membrane transport of anthracycline derivatives in drug-resistant and drug sensitive K562 cells. Eur J Biochem 1991; 196: 483-91.
19. Tritton TR, Yee G. The anticancer agent adriamycin can be actively cytotoxic without entering cells. Science 1982; 217: 248-50.
20. Jaffrézou JP, Levade T, Bettaieb, A, et al. Daunorubicin-induced apoptosis: triggering of ceramide generation through sphingomyelin hydrolysis. EMBO J 1996; 15: 2417-24.
21. Berman E, Mc Bride L. Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells. Blood 1992; 79: 3267-73.
22. Genne P, Dimanche-Boitrel MT, Mauvernay RY, et al. Cinchonine, a potent efflux inhibitor to circumvent anthracycline resistance in vivo. Cancer Res 1992; 52: 2797-801.
23. Bennis S, Ichas F, Robert J. Differential effects of verapamil and quinine on the reversal of doxorubicin resistance in a human leukaemia cell line. Int J Cancer 1995; 62: 283-90.
24. Schuurhuis GJ, van Heijningen THM, Cervantes A, et al. Changes in subcellular doxorubicin distribution and cellular accumulation alone can largely account for doxorubicin resistance in SW-1573 lung cancer and MCF-7 breast cancer multidrug resistant tumour cells. Br J Cancer 1993; 68: 898-908.
25. Abbas-Zadegan MR, Cress AE, Futscher BW, Bellamy WT, Dalton WS. Evidence for cytoplasmic P-glycoprotein location associated with increased multidrug resistance and resistance to chemosensitizers. Cancer Res 1996; 56: 5435-42.